Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy
IntroductionThe application of programmed cell death protein 1 (PD-1) antibodies has brought significant benefits to patients with non-small cell lung cancer (NSCLC). However, not all patients respond to PD-1 immune therapy. The aim of this study was to identify response biomarkers to predict the ef...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521708/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725760337608704 |
|---|---|
| author | Jing Cao Yuehua Zhang Shenghu Guo Zheng Wu Xiaojin Guo Rongze Zhang Lei Zhang Ya Liu Xing Li Chunwang Yang Dongwei He Lu Bai Tingting Lv Yong Xie Chengjing Huang Shuang Xiao Anyi Deng Jiawei Li Jiawei Li Jiaxing Zhu Zhenghu Jia Zhenghu Jia Zhinan Yin Zhiyu Wang |
| author_facet | Jing Cao Yuehua Zhang Shenghu Guo Zheng Wu Xiaojin Guo Rongze Zhang Lei Zhang Ya Liu Xing Li Chunwang Yang Dongwei He Lu Bai Tingting Lv Yong Xie Chengjing Huang Shuang Xiao Anyi Deng Jiawei Li Jiawei Li Jiaxing Zhu Zhenghu Jia Zhenghu Jia Zhinan Yin Zhiyu Wang |
| author_sort | Jing Cao |
| collection | DOAJ |
| description | IntroductionThe application of programmed cell death protein 1 (PD-1) antibodies has brought significant benefits to patients with non-small cell lung cancer (NSCLC). However, not all patients respond to PD-1 immune therapy. The aim of this study was to identify response biomarkers to predict the efficacy of chemotherapy combined with anti-PD-1 therapy in NSCLC patients.MethodsThirty-two NSCLC patients receiving chemotherapy combined with anti-PD-1 therapy were recruited, and peripheral blood samples were collected before and after treatment. Flow cytometry was used to detect the proportions of circulating T-cell subsets, and cytokines in the blood serum were detected via ELISA.ResultsThe results revealed that, among the CR/PR group (CR, complete response; PR, partial response; n = 22), the proportions of CD3+TIM-3+PD-1+, CD3+CD4+TIM-3+PD-1+, and CD3+CD8+TIM-3+PD-1+, CD3+γδT+PD-1+, CD3+γδT+Vδ1+PD-1+, and CD3+γδT+Vδ2+PD-1+T cells were lower after treatment, with no significant differences found between the stable disease (SD) and progressive disease (PD) groups (n = 10). Some proinflammatory cytokines are highly expressed in patients with NSCLC.DiscussionThis study suggests that monitoring changes in immune biomarkers in the circulating cells of NSCLC patients may help differentiate CR/PR patients from SD/PD patients, providing a potential new approach for assessing the efficacy of chemotherapy combined with anti-PD-1 therapy. |
| format | Article |
| id | doaj-art-32745647132641d3b048c9b92cdcc2a3 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-32745647132641d3b048c9b92cdcc2a32025-08-20T03:10:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.15217081521708Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapyJing Cao0Yuehua Zhang1Shenghu Guo2Zheng Wu3Xiaojin Guo4Rongze Zhang5Lei Zhang6Ya Liu7Xing Li8Chunwang Yang9Dongwei He10Lu Bai11Tingting Lv12Yong Xie13Chengjing Huang14Shuang Xiao15Anyi Deng16Jiawei Li17Jiawei Li18Jiaxing Zhu19Zhenghu Jia20Zhenghu Jia21Zhinan Yin22Zhiyu Wang23Department of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Obstetrics and Gynecology, The First People’s Hospital of Foshan, Foshan, Guangdong, ChinaResearch and Development Department, Jiangxi Purui Biotechnology Co., Ltd., Ganzhou, Jiangxi, ChinaThe Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, ChinaThe Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, ChinaResearch and Development Department, Jiangxi Purui Biotechnology Co., Ltd., Ganzhou, Jiangxi, ChinaThe Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, ChinaDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, ChinaThe Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, ChinaDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, ChinaThe Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, ChinaDepartment of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaIntroductionThe application of programmed cell death protein 1 (PD-1) antibodies has brought significant benefits to patients with non-small cell lung cancer (NSCLC). However, not all patients respond to PD-1 immune therapy. The aim of this study was to identify response biomarkers to predict the efficacy of chemotherapy combined with anti-PD-1 therapy in NSCLC patients.MethodsThirty-two NSCLC patients receiving chemotherapy combined with anti-PD-1 therapy were recruited, and peripheral blood samples were collected before and after treatment. Flow cytometry was used to detect the proportions of circulating T-cell subsets, and cytokines in the blood serum were detected via ELISA.ResultsThe results revealed that, among the CR/PR group (CR, complete response; PR, partial response; n = 22), the proportions of CD3+TIM-3+PD-1+, CD3+CD4+TIM-3+PD-1+, and CD3+CD8+TIM-3+PD-1+, CD3+γδT+PD-1+, CD3+γδT+Vδ1+PD-1+, and CD3+γδT+Vδ2+PD-1+T cells were lower after treatment, with no significant differences found between the stable disease (SD) and progressive disease (PD) groups (n = 10). Some proinflammatory cytokines are highly expressed in patients with NSCLC.DiscussionThis study suggests that monitoring changes in immune biomarkers in the circulating cells of NSCLC patients may help differentiate CR/PR patients from SD/PD patients, providing a potential new approach for assessing the efficacy of chemotherapy combined with anti-PD-1 therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521708/fullimmune biomarkersNSCLCanti-PD-1 therapyTIM-3cytokines |
| spellingShingle | Jing Cao Yuehua Zhang Shenghu Guo Zheng Wu Xiaojin Guo Rongze Zhang Lei Zhang Ya Liu Xing Li Chunwang Yang Dongwei He Lu Bai Tingting Lv Yong Xie Chengjing Huang Shuang Xiao Anyi Deng Jiawei Li Jiawei Li Jiaxing Zhu Zhenghu Jia Zhenghu Jia Zhinan Yin Zhiyu Wang Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy Frontiers in Immunology immune biomarkers NSCLC anti-PD-1 therapy TIM-3 cytokines |
| title | Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy |
| title_full | Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy |
| title_fullStr | Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy |
| title_full_unstemmed | Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy |
| title_short | Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy |
| title_sort | immune biomarkers in circulating cells of nsclc patients can effectively evaluate the efficacy of chemotherapy combined with anti pd 1 therapy |
| topic | immune biomarkers NSCLC anti-PD-1 therapy TIM-3 cytokines |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521708/full |
| work_keys_str_mv | AT jingcao immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT yuehuazhang immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT shenghuguo immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT zhengwu immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT xiaojinguo immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT rongzezhang immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT leizhang immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT yaliu immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT xingli immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT chunwangyang immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT dongweihe immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT lubai immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT tingtinglv immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT yongxie immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT chengjinghuang immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT shuangxiao immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT anyideng immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT jiaweili immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT jiaweili immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT jiaxingzhu immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT zhenghujia immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT zhenghujia immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT zhinanyin immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy AT zhiyuwang immunebiomarkersincirculatingcellsofnsclcpatientscaneffectivelyevaluatetheefficacyofchemotherapycombinedwithantipd1therapy |